Email
Location
- Proof of concept (2019) — ENHANCIDO: Commercialization of catalytic enhancers targeting IDO1 for multiple sclerosis
- Proof of concept (2017) — DIDO-MS: Commercialization of a first in class multiple sclerosis drug
- Advanced (2012) — DIDO: Innovative drugs targeting IDO molecular dynamics in autoimmunity and neoplasia